These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32721508)

  • 1. Vitamin K
    Dawood M; Hegazy MF; Elbadawi M; Fleischer E; Klinger A; Bringmann G; Kuntner C; Shan L; Efferth T
    Biochem Pharmacol; 2020 Oct; 180():114176. PubMed ID: 32721508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
    Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
    Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells.
    Lu X; Yan G; Dawood M; Klauck SM; Sugimoto Y; Klinger A; Fleischer E; Shan L; Efferth T
    Biochem Pharmacol; 2021 Dec; 194():114677. PubMed ID: 34265280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin K
    Hegazy MF; Fukaya M; Dawood M; Yan G; Klinger A; Fleischer E; Zaglool AW; Efferth T
    Invest New Drugs; 2020 Jun; 38(3):650-661. PubMed ID: 31254176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
    Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T
    Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer.
    Jung KH; Noh JH; Kim JK; Eun JW; Bae HJ; Chang YG; Kim MG; Park WS; Lee JY; Lee SY; Chu IS; Nam SW
    Hepatology; 2012 Aug; 56(2):644-57. PubMed ID: 22392728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
    Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
    Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy.
    Park SJ; Joo SH; Lee N; Jang WJ; Seo JH; Jeong CH
    Arch Pharm Res; 2021 Dec; 44(12):1062-1075. PubMed ID: 34761352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
    Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
    Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
    Liu JR; Yu CW; Hung PY; Hsin LW; Chern JW
    Biochem Pharmacol; 2019 May; 163():458-471. PubMed ID: 30885763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
    Osko JD; Christianson DW
    Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
    Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
    Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.
    Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Yao R; Xu K
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30782785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer.
    Seidel C; Schnekenburger M; Mazumder A; Teiten MH; Kirsch G; Dicato M; Diederich M
    Biochem Pharmacol; 2016 Jan; 99():31-52. PubMed ID: 26549368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HDAC6 by Tubastatin A reduces chondrocyte oxidative stress in chondrocytes and ameliorates mouse osteoarthritis by activating autophagy.
    Shen Z; Ji K; Cai Z; Huang C; He X; Xu H; Chen G
    Aging (Albany NY); 2021 Mar; 13(7):9820-9837. PubMed ID: 33744850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
    Kaliszczak M; Trousil S; Åberg O; Perumal M; Nguyen QD; Aboagye EO
    Br J Cancer; 2013 Feb; 108(2):342-50. PubMed ID: 23322205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a fluorescent probe with HDAC6 selective inhibition.
    Zhang Y; Yan J; Yao TP
    Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
    Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.